PharmGED: Pharmacogenetic effect database

Nucleic Acids Research

Volumn 35, Issue SUPPL. 1, 2007, Pages

  Zheng, C J ^a   Han, L Y ^a   Xie, B ^a   Liew, C Y ^a   Ong, S ^a   Cui, J ^a   Zhang, H L ^a   Tang, Z Q ^a   Gan, S H ^a   Jiang, L ^a   Chen, Y Z ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CAPECITABINE; EFAVIRENZ; FLUVOXAMINE; IRINOTECAN; ISONIAZID; LIGAND; LOXAPINE; MILNACIPRAN; NELFINAVIR; PAROXETINE; RISPERIDONE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN; TRANILAST;

ACCESS TO INFORMATION; ARTICLE; COMPUTER PREDICTION; DNA POLYMORPHISM; DRUG RESEARCH; DRUG RESPONSE; GENE FUNCTION; GENE SEQUENCE; GENETIC CODE; GENETIC DATABASE; GENETIC VARIABILITY; INTERNET; MEDICAL INFORMATION; PHARMACOGENETIC EFFECT DATABASE; PHARMACOGENOMICS; PRIORITY JOURNAL;

ANIMALS; DATABASES, GENETIC; INTERNET; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTEINS; USER-COMPUTER INTERFACE;

EID: 33846041970     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkl853     Document Type: Article

References (44)

1. Evans,W.E. and Relling,M.V. (2004) Moving towards individualized medicine with pharmacogenomics. Nature, 429, 464-468.
2. Lindpaintner,K. (2003) Pharmacogenetics and the future of medical practice. J. Mol. Med., 81, 141-153.
3. Marzolini,C., Paus,E., Buclin,T. and Kim,R.B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin. Pharmacol. Ther., 75, 13-33.
4. Evans,W.E., Hon,Y.Y., Bomgaars,L., Coutre,S., Holdsworth,M., Janco,R., Kalwinsky,D., Keller,F., Khatib,Z., Margolin,J. et al. (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J. Clin. Oncol., 19, 2293-2301.
5. Marshall,A. (1997) Laying the foundations for personalized medicines. Nat. Biotechnol., 15, 954-957.
6. Altman,R.B. and Klein,T.E. (2002) Challenges for biomedical informatics and pharmacogenomics. Annu. Rev. Pharmacol. Toxicol., 42, 113-133.
7. Kalow,W. (2001) Pharmacogenetics, pharmacogenomics, and pharmacobiology. Clin. Pharmacol. Ther., 70, 1-4.
8. Marshall,A. (1997) Getting the right drug into the right patient. Nat. Biotechnol., 15, 1249-1252.
9. Nicholls,H. (2003) Improving drug response with pharmacogenomics. Drug Discov. Today, 8, 281-282.
10. Zheng,C.J., Sun,L.Z., Han,L.Y., Ji,Z.L., Chen,X. and Chen,Y.Z. (2004) Drug ADME-associated protein database as a resource for facilitating pharmacogenomics research. Drug Dev. Res., 62, 134-142.
11. Gurwitz,D., Lunshof,J.E. and Altman,R.B. (2006) A call for the creation of personalized medicine databases. Nature Rev. Drug Discov., 5, 23-26.
12. Vyas,H. and Summers,R. (2005) An information-driven approach to pharmacogenomics. Pharmacogenomics, 6, 473-480.
13. Freimuth,R.R., Stormo,G.D. and McLeod,H.L. (2005) PolyMAPr: Programs for polymorphism database mining, annotation, and functional analysis. Hum. Mutat., 25, 110-117.
14. Klein,T.E., Chang,J.T., Cho,M.K., Easton,K.L., Fergerson,R., Hewett,M., Lin,Z., Liu,Y., Liu,S., Oliver,D.E. et al. (2001) Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J., 1, 167-170.
15. Ji,Z.L., Han,L.Y., Yap,C.W., Sun,L.Z., Chen,X. and Chen,Y.Z. (2003) Drug Adverse Reaction Target Database (DART): Proteins related to adverse drug reactions. Drug Saf., 26, 685-690.
16. Ji,Z.L., Sun,L.Z., Chen,X., Zheng,C.J., Yao,L.X., Han,L.Y., Cao,Z.W., Wang,J.F., Yeo,W.K., Cai,C.Z. et al. (2003) Internet resources for proteins associated with drug therapeutic effects, adverse reactions and ADME. Drug Discov. Today, 8, 526-529.
17. Sun,L.Z., Ji,Z.L., Chen,X., Wang,J.F. and Chen,Y.Z. (2002) ADME-AP: A database of ADME associated proteins. Bioinformatics, 18, 1699-1700.
18. Chen,X., Ji,Z.L. and Chen,Y.Z. (2002) TTD: Therapeutic Target Database. Nucleic Acids Res., 30, 412-415.
19. Ozawa,N., Shimizu,T., Morita,R., Yokono,Y., Ochiai,T., Munesada,K., Ohashi,A., Aida,Y., Hama,Y., Taki,K. et al. (2004) Transporter database, TP-Search: A web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res., 21, 2133-2134.
20. Iida,A., Saito,S., Sekine,A., Takahashi,A., Kamatani,N. and Nakamura,Y. (2006) Japanese single nucleotide polymorphism database for 267 possible drug-related genes. Cancer Sci., 97, 16-24.
21. Salter,A.H. (2005) Large-scale databases in toxicogenomics. Pharmacogenomics, 6, 749-754.
22. Wheeler,D.L., Barrett,T., Benson,D.A., Bryant,S.H., Canese,K., Chetvernin,V., Church,D.M., DiCuccio,M., Edgar,R., Federhen,S. et al. (2006) Database resources of the national center for biotechnology information. Nucleic Acids Res., 34, D173-D180.
23. Hosford,D.A., Lai,E.H., Riley,J.H., Xu,C.F., Danoff,T.M. and Roses,A.D. (2004) Pharmacogenetics to predict drug-related adverse events. Toxicol. Pathol., 32, 9-12.
24. Ranganathan,P., Eisen,S., Yokoyama,W.M. and McLeod,H.L. (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann. Rheum. Dis., 62, 4-9.
25. Hiratsuka,M., Kishikawa,Y., Takekuma,Y., Matsuura,M., Narahara,K., Inoue,T., Hamdy,S.I., Endo,N., Goto,J. and Mizugaki,M. (2002) Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab. Pharmacokinet., 17, 357-362.
26. Yoshida,K., Takahashi,H., Higuchi,H., Kamata,M., Ito,K., Sato,K., Naito,S., Shimizu,T., Itoh,K., Inoue,K. et al. (2004) Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatr., 161, 1575-1580.
27. Carlini,L.E., Meropol,N.J., Bever,J., Andria,M.L., Hilt,T., Gold,P., Rogatko,A., Wang,H. and Blanchard,R.L. (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res., 11, 1226-1236.
28. Anttila,S., Illi,A., Kampman,O., Mattila,K.M., Lehtimaki,T. and Leinonen,E. (2004) Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics, 14, 303-307.
29. Kajinami,K., Brousseau,M.E., Ordovas,J.M. and Schaefer,E.J. (2004) Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis, 175, 287-293.
30. Zazzi,M., Romano,L., Venturi,G., Shafer,R.W., Reid,C., Dal Bello,F., Parolin,C., Palu,G. and Valensin,P.E. (2004) Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. J. Antimicrob. Chemother., 53, 356-360.
31. Debouck,C. and Metcalf,B. (2000) The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol., 40, 193-207.
32. Eddershaw,P.J., Beresford,A.P. and Bayliss,M.K. (2000) ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today, 5, 409-414.
33. Li,A.P. (2001) Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today, 6, 357-366.
34. Lin,J.H. and Lu,A.Y. (1997) Role of pharmacokineties and metabolism in drug discovery and development. Pharmacol. Rev., 49, 403-449.
35. Mobley,C. and Hochhaus,G. (2001) Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov. Today, 6, 367-375.
36. Dove,A. (1999) Proteomics: Translating genomics into products? Nat. Biotechnol., 17, 233-236.
37. Scharpe,S. and De Meester,I. (2001) Peptide truncation by dipeptidyl peptidase IV: A new pathway for drug discovery? Verh. K. Acad, Geneeskd Belg., 63, 5-32; discussion 32-33.
38. Basile,V.S., Ozdemir,V., Masellis,M., Walker,M.L., Meltzer,H.Y., Lieberman,J.A., Potkin,S.G., Alva,G., Kalow,W., Macciardi,F.M. et al. (2000) A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia. Mol. Psychiatr., 5, 410-417.
39. Kapitany,T., Meszaros,K., Lenzinger,E., Schindler,S.D., Barnas,C., Fuchs,K., Sieghart,W., Aschauer,H.N. and Kasper,S. (1998) Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res., 32, 101-106.
40. Serretti,A., Zanardi,R., Rossini,D., Cusin,C., Lilli,R. and Smeraldi,E. (2001) Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatr., 6, 586-592.
41. Smits,K.M., Smits,L.J., Schouten,J.S., Stelma,F.F., Nelemans,P. and Prins,M.H. (2004) Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol. Psychiatr., 9, 433-441.
42. Rau,T., Wohlleben,G., Wuttke,H., Thuerauf,N., Lunkenheimer,J., Lanczik,M. and Eschenhagen,T. (2004) CYP2D6 genotype: Impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin. Pharmacol. Ther., 75, 386-393.
43. Siddiqui,A., Kerb,R., Weale,M.E., Brinkmann,U., Smith,A., Goldstein,D.B., Wood,N.W. and Sisodiya,S.M. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med., 348, 1442-1448.
44. Saitoh,A., Singh,K.K., Powell,C.A., Fenton,T., Fletcher,C.V., Brundage,R., Starr,S. and Spector,S.A. (2005) An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS, 19, 371-380.